Results 61 to 70 of about 649,205 (258)

Tuberculosis

open access: yesSouthern Medical Journal, 1910
n ...
openaire   +2 more sources

Synergistic Advanced Oxidation and Physicochemical Treatment Strategies for Antibiotic Removal and Resistance Mitigation in Water

open access: yesAsia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT The presence of antibiotics in water not only causes environmental pollution but also increases the growth of antibiotic‐resistant bacterial genes, which pose serious threats to human beings and other water residents. Large numbers of people are reportedly affected by the resistant bacterial genes, as many broad‐spectrum antibiotics are not ...
Amir Zada, Shohreh Azizi
wiley   +1 more source

Integrating One Health to Mitigate the Emergence and Spread of Antimicrobial Resistance in Livestock and Aquaculture

open access: yesAnimal Research and One Health, EarlyView.
Antimicrobial resistance (AMR) is an escalating global threat driven by antimicrobial use in aquaculture and livestock. Resistant pathogens and genes can spread across humans, animals, and the environment through interconnected ecosystems. Using a One Health approach, this review emphasizes antimicrobial stewardship, regulatory strengthening, enhanced ...
Mir Mohammad Ali   +10 more
wiley   +1 more source

Tuberculosis : general information [Spanish]

open access: yes
Tuberculosis : general information [Spanish]La tuberculosis (TB, por sus siglas en ingl\ue9s) es una enfermedad causada por microbios que se propagan de una persona a otra a trav\ue9s del aire. La tuberculosis generalmente afecta los pulmones, pero tambi\

core  

Human resources for control of tuberculosis and HIV-associated tuberculosis.

open access: yes, 2005
The global targets for tuberculosis (TB) control were postponed from 2000 to 2005, but on current evidence a further postponement may be necessary.
Zachariah, R   +7 more
core  

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie   +12 more
wiley   +1 more source

The doctor and tuberculosis of the future

open access: yes, 1937
Third annual John W. Bell Tuberculosis Lecture delivered at a meeting of the Hennepin Coumy (Minnesota) Medical Society, December 7, 1936, through the courtesy of the Hennepin County Tuberculosis Association.
National Tuberculosis Association
core  

Evaluating the Potential Infectious Risk Profile of Biologics in Chronic Rhinosinusitis With Nasal Polyposis

open access: yes
International Forum of Allergy &Rhinology, EarlyView.
Maxime Fieux   +2 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy